Phagelux Revenue and Competitors
Estimated Revenue & Valuation
- Phagelux's estimated annual revenue is currently $2.5M per year.
- Phagelux's estimated revenue per employee is $155,000
Employee Data
- Phagelux has 16 Employees.
- Phagelux grew their employee count by -11% last year.
Phagelux's People
Name | Title | Email/Phone |
---|
Phagelux Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Phagelux?
Phagelux, Inc. (“Phagelux') is a China-based company that utilizes phages to solve bacterial problems in multiple fields including crop diseases, animal health, food safety and general sanitary. In 2014, Phagelux will start to work on human health issues. Phagelux develops its products either through third party out-sourced service providers or in its own lab. Phagelux also in-licenses phage products from third parties. Phagelux sell its products directly within China and partners with multinational companies for outside markets. Phagelux gives preferences to global partners with at least one phage product already in the market.
keywords:N/AN/A
Total Funding
16
Number of Employees
$2.5M
Revenue (est)
-11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Phagelux News
The major key players are - NPO Microgen, Proteon Pharmaceuticals, Phagelux, Intralytix, Micreos, Eliava BioPreparations, Locus Biosciences...
... Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux, Inc., Nextbiotics, InnoPhage, Ltd.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 38 | 0% | N/A |
#2 | $6.4M | 39 | -11% | N/A |
#3 | $8.6M | 40 | 14% | N/A |
#4 | N/A | 41 | 5% | N/A |
#5 | $9.7M | 44 | 2% | N/A |